IceCure Medical Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

IceCure Medical wird ein Gewinn- und Umsatzwachstum von 62.7% bzw. 57.9% pro Jahr prognostiziert, während der Gewinn pro Aktie um 64.2% pro Jahr wachsen soll.

Wichtige Informationen

62.7%

Wachstumsrate der Gewinne

64.2%

EPS-Wachstumsrate

Medical Equipment Gewinnwachstum	17.1%
Wachstumsrate der Einnahmen	57.9%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	26 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:ICCM - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	33	-2	-11	N/A	1
12/31/2025	8	-13	-13	N/A	3
12/31/2024	3	-14	-15	N/A	2
9/30/2024	4	-14	-11	-11	N/A
6/30/2024	3	-14	-11	-11	N/A
3/31/2024	3	-14	-13	-12	N/A
12/31/2023	3	-15	-13	-13	N/A
9/30/2023	3	-16	-15	-14	N/A
6/30/2023	3	-16	-15	-14	N/A
3/31/2023	3	-16	-15	-14	N/A
12/31/2022	3	-17	-15	-14	N/A
9/30/2022	4	-16	-17	-16	N/A
6/30/2022	4	-15	-17	-16	N/A
3/31/2022	3	-13	-14	-14	N/A
12/31/2021	4	-10	-13	-13	N/A
9/30/2021	4	-8	-9	-8	N/A
6/30/2021	4	-6	-7	-6	N/A
3/31/2021	4	-4	-5	-5	N/A
12/31/2020	4	-4	-4	-4	N/A
9/30/2020	3	-4	-2	-2	N/A
6/30/2020	3	-4	-1	0	N/A
3/31/2020	2	-4	-1	-1	N/A
12/31/2019	2	-5	-2	-2	N/A
9/30/2019	1	-5	N/A	N/A	N/A
6/30/2019	1	-4	-4	-4	N/A
3/31/2019	1	-4	-4	-4	N/A
12/31/2018	1	-4	-3	-3	N/A
9/30/2018	1	-3	N/A	N/A	N/A
6/30/2018	1	-3	N/A	-3	N/A
3/31/2018	1	-3	N/A	-3	N/A
12/31/2017	1	-3	N/A	-3	N/A
9/30/2017	1	-3	N/A	-3	N/A
6/30/2017	1	-3	N/A	-3	N/A
3/31/2017	1	-3	N/A	-3	N/A
12/31/2016	1	-3	N/A	-3	N/A
9/30/2016	1	-3	N/A	-3	N/A
6/30/2016	1	-4	N/A	-4	N/A
3/31/2016	1	-4	N/A	-3	N/A
12/31/2015	1	-4	N/A	-3	N/A
9/30/2015	1	-4	N/A	-3	N/A
6/30/2015	1	-4	N/A	-3	N/A
3/31/2015	1	-4	N/A	-3	N/A
12/31/2014	1	-5	N/A	-3	N/A
9/30/2014	1	-5	N/A	-4	N/A
6/30/2014	1	-5	N/A	-4	N/A
3/31/2014	0	-5	N/A	-3	N/A
12/31/2013	0	-5	N/A	-3	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ICCM wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (2.6%).

Ertrag vs. Markt: ICCM wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: ICCM wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: ICCMDie Einnahmen des Unternehmens (57.9% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.9% pro Jahr).

Hohe Wachstumseinnahmen: ICCMDie Einnahmen des Unternehmens (57.9% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von ICCM in 3 Jahren voraussichtlich hoch sein wird

IceCure Medical Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Forecast to breakeven in 2026

Price target increased by 14% to US$3.33

Forecast to breakeven in 2026

Price target decreased by 15% to US$3.41

Price target decreased by 14% to US$3.96

Price target decreased to US$4.58

Recent updates

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

IceCure Medical Ltd to Report Q3, 2024 Results on Nov 26, 2024

IceCure Medical Ltd has filed a Follow-on Equity Offering.

IceCure Medical Ltd. Announces Study Publishes in British Journal of Radiology Demonstrates IceCure's ProSense is Safe Procedure with 97.7% Technical Success Rate in Treating Tumors of Lung, Bone, and Soft Tissues

IceCure Medical Ltd. Announces FDA Advisory Panel Meeting Date for Marketing Authorization of ProSense in Early-Stage Low Risk Breast Cancer Scheduled for November 7, 2024

U.S. Patent and Trademark Office Grants Notice of Allowance for Additional Patent on IceCure Medical Ltd.'s Novel Cryogenic Pump Technology

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Forecast to breakeven in 2026

IceCure Medical Ltd Announces the Publication of an Independent Study of Patients Who Chose Cryoablation for the Treatment of Early Breast Cancer in Non-Surgical Patients

IceCure Medical Ltd to Report Q2, 2024 Results on Aug 20, 2024

IceCure Medical Ltd. Announces Positive Data from the Largest Multi-Institutional Study of Its Kind: "Cryoablation of Primary Breast Cancer in Patients Ineligible for Clinical Trials

Is IceCure Medical (NASDAQ:ICCM) In A Good Position To Invest In Growth?

New minor risk - Share price stability

IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification

IceCure Medical Ltd. Announces the Publication of an Independent Study Evaluating its Cryoablation System ProSense

U.S. Food and Drug Administration Grants Regulatory Clearance to IceCure for Next-Gen XSense Cryoablation System with CryoProbes

New minor risk - Shareholder dilution

FDA to Convene Advisory Panel for Review of IceCure Medical Ltd.'s De Novo Marketing Clearance Request for ProSense®, Decision Expected Early 2025

First quarter 2024 earnings: EPS in line with expectations, revenues disappoint

IceCure Medical Ltd to Report Q1, 2024 Results on May 28, 2024

IceCure Medical Ltd, Annual General Meeting, May 20, 2024

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Icecure Submits FDA Regulatory Filing for New Xsense™ Cryoablation System with Cryoprobes

IceCure Medical Ltd to Report Fiscal Year 2023 Results on Apr 03, 2024

Price target increased by 14% to US$3.33

IceCure Medical Ltd. Reports Positive Topline Results from ICE3 Cryoablation Breast Cancer Study

IceCure Medical Ltd. Announces Results from an Independent Study

Icecure Medical Ltd. Announces New Data from A Preliminary, Independent Breast Cancer Study

IceCure Medical Ltd has filed a Follow-on Equity Offering in the amount of $9.7 million.

IceCure Medical Regains Compliance with Nasdaq Minimum Closing Bid Price Rule

Forecast to breakeven in 2026

IceCure Medical Ltd. Announces the Publication of a Study Called "Cryoablation Allows the Ultimate De-Escalation of Surgical Therapy for Select Breast Cancer Patients

IceCure Medical Ltd. Announces Release of a Study in a Series of Independent Studies of ProSense

We're Keeping An Eye On IceCure Medical's (NASDAQ:ICCM) Cash Burn Rate

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

IceCure Medical Files Appeal with U.S. FDA Requesting a Review of its De Novo Classification for ProSense in Early-Stage Breast Cancer

IceCure Medical Ltd to Report Q3, 2023 Results on Nov 15, 2023

Icecure Medical Ltd. Announces Provides Update on Substantial Evidence-Based Data Currently Being Generated by 19 Ongoing Studies Using IceCure Medical's Prosense Cryoablation System

New major risk - Revenue and earnings growth

IceCure Medical Ltd. Receives FDA Response to De Novo Classification Request for Breast Cancer

Price target decreased by 15% to US$3.41

Icecure Medical's Prosense Cryoablation System Receives Regulatory Approval in Brazil

Icecure Medical's Prosense Cryoablation System Receives Regulatory Approval in Brazil

Second quarter 2023 earnings: EPS misses analyst expectations

IceCure Medical Ltd to Report Q2, 2023 Results on Aug 14, 2023

Is IceCure Medical (NASDAQ:ICCM) In A Good Position To Deliver On Growth Plans?

Health Canada Approves Icecure Medical's Minimally Invasive Prosense Cryoablation System

New major risk - Financial position

New major risk - Revenue and earnings growth

IceCure Medical Ltd to Report Q1, 2023 Results on May 22, 2023

Insufficient new directors

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Price target decreased by 14% to US$3.96

IceCure Medical Ltd Receives Notice of Allowance from the U.S. Patent and Trademark Office for Its Patent Application Titled Cryogen Pump

IceCure Medical Ltd Receives Notice of Patent Allowance in Japan for A Novel Cryogenic Pump for Its Next-Generation Cryoablation Systems

IceCure Medical Ltd Announces Interim Results from the ICESECRET Study for the Treatment of Patients with Small Renal Masses

IceCure Appoints Vincent Chun Hung Chan to Serve as an Independent Director on its Board of Directors

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

IceCure Medical Ltd to Report Nine Months, 2022 Results on Dec 05, 2022

Price target decreased to US$4.58

IceCure's ProSense® Achieves Significant Milestone in Medicare Coverage of Breast Cancer Procedures

Price target decreased to US$4.58

IceCure Medical Ltd. Files De Novo Classification Request with the FDA for Marketing Authorization of ProSense with Breakthrough Indication: Early-Stage Low-Risk Breast Cancer Patients at High Risk to Surgery

IceCure gains 19% on seeking FDA nod for cancer treatment

IceCure Medical Ltd Submits Regulatory Filing in Vietnam for Approval of Prosense®

Second quarter 2022 earnings released

IceCure Medical Ltd to Report Q2, 2022 Results on Aug 15, 2022

IceCure Medical Ltd Announces Regulatory Filing Submission for Approval of ProSense® in Canada for Indications Including Ablation of Benign and Malignant Breast Tumors

IceCure files application for approval of ProSense in Canada for tumors